Isotechnika Advances Kidney Transplant Drug

Isotechnika is now enrolling newly-transplanted kidney transplant patients in a phase II clinical trial for the immunosuppressant drug, ISA247. The goal of the clinical drug trial is to determine the most appropriate dose, resulting in the least amount of side affects as compared to other immunosuppressant therapies.

According to a news release from DATAMONITOR NEWSWIRE, “the primary endpoint of the trial is defined as non-inferiority in rejection episodes in patients receiving ISA247 for six months as compared to the control group that will receive tacrolimus, an alternative immunosuppressant drug.”

Kidney function, as well as hypertension, hyperlipidemia and new onset diabetes mellitus, will also be monitored throughout the trial. 

The trial will be performed in 34 centers across North America, including 29 centers in the United States and five centers in Canada. A total of 332 newly-transplanted kidney transplant patients will be enrolled in this trial.

"We are excited to move ISA247 forward in the area of transplantation as well as for the treatment of psoriasis," stated Dr Randall Yatscoff, Isotechnika's president & CEO (DATAMONITOR NEWSWIRE).